Drug Resistance Updates
Volume 13, Issue 4 , Pages 132-138 , August 2010

Resistance to polymyxins: Mechanisms, frequency and treatment options

  • Matthew E. Falagas

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
    • Department of Medicine, Henry Dunant Hospital, Athens, Greece
    • Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA
    • Corresponding Author InformationCorresponding author at: Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 15 123, Marousi, Greece. Tel.: +30 694 611 0000; fax: +30 210 683 9605.
    • ,
  • Petros I. Rafailidis

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
    • Department of Medicine, Henry Dunant Hospital, Athens, Greece
    • ,
  • Dimitrios K. Matthaiou

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
    • Department of Medicine, “G. Gennimatas” General Hospital, Thessaloniki, Greece

Received 27 April 2010 ,Revised 24 May 2010 ,Accepted 24 May 2010.

References 

  1. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 2009;53:3628–3634
  2. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect Dis. 2008;46:567–570
  3. Bell A, Hancock RE. Outer membrane protein H1 of Pseudomonas aeruginosa: purification of the protein and cloning and nucleotide sequence of the gene. J. Bacteriol. 1989;171:3211–3217
  4. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol. Microbiol. 2000;37:67–80
  5. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 2005;49:3018–3020
  6. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 2005;56:128–132
  7. Breazeale SD, Ribeiro AA, McClerren AL, Raetz CR. A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-amino-4-deoxy-l-arabinose. Identification and function of UDP-4-deoxy-4-formamido-l-arabinose. J. Biol. Chem. 2005;280:14154–14167
  8. Brown DA, Tsang JC. Chemical and electrophoretic changes induced by polymyxin B on outer membrane components from Serratia marcescens. J. Antibiot (Tokyo). 1978;31:603–609
  9. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun. 2004;72:7107–7114
  10. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2008;52:570–573
  11. Castanheira, M., Sader, H.S., Jones, R.N., Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist.
  12. Cezario RC, Duarte De Morais L, Ferreira JC, Costa-Pinto RM, da Costa Darini AL, Gontijo-Filho PP. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm Infect. Microbiol. Clin. 2009;27:269–274
  13. Clausell A, Garcia-Subirats M, Pujol M, Busquets MA, Rabanal F, Cajal Y. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J. Phys. Chem. B. 2007;111:551–563
  14. Davis SD, Iannetta A, Wedgwood RJ. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J. Infect. Dis. 1971;124:610–612
  15. Dobrewski R, Savov E, Bernards AT, van den Barselaar M, Nordmann P, van den Broek PJ, et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin. Microbiol. Infect. 2006;12:1135–1137
  16. Eser OK, Ergin A, Hascelik G. Antimicrobial resistance and existence of metallo-beta-lactamase in Acinetobacter species isolated from adult patients. Mikrobiyol Bul. 2009;43:383–390
  17. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis. 2005;5:24
  18. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 2005;40:1333–1341
  19. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents. 2009;34:111–120
  20. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK. Heteroresistance: a concern of increasing clinical significance?. Clin. Microbiol. Infect. 2008;14:101–104
  21. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents. 2010;35:240–243
  22. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents. 2010;35:194–199
  23. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents. 2008;32:450–454
  24. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 2008;46:1069–1077
  25. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn. Microbiol. Infect. Dis. 2006;56:427–436
  26. Fica CA, Cespedes JI, Gompertz GM, Jalon VM, Sakurada ZA, Saez LE. Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli. Rev. Chilena Infectol. 2007;24:360–367
  27. Fu W, Yang F, Kang X, Zhang X, Li Y, Xia B, et al. First structure of the polymyxin resistance proteins. Biochem. Biophys. Res. Commun. 2007;361:1033–1037
  28. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin. Microbiol. Infect. 2006;12:315–321
  29. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 2001;39:183–190
  30. Garcia-Penuela E, Aznar E, Alarcon T, Lopez-Brea M. Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs. Hong Kong. Rev. Esp Quimioter. 2006;19:45–50
  31. Gatzeva-Topalova PZ, May AP, Sousa MC. Crystal structure and mechanism of the Escherichia coli ArnA (PmrI) transformylase domain. An enzyme for lipid A modification with 4-amino-4-deoxy-l-arabinose and polymyxin resistance. Biochemistry. 2005;44:5328–5338
  32. Gatzeva-Topalova PZ, May AP, Sousa MC. Crystal structure of Escherichia coli ArnA (PmrI) decarboxylase domain. A key enzyme for lipid A modification with 4-amino-4-deoxy-L-arabinose and polymyxin resistance. Biochemistry. 2004;43:13370–13379
  33. Gatzeva-Topalova PZ, May AP, Sousa MC. Structure and mechanism of ArnA: conformational change implies ordered dehydrogenase mechanism in key enzyme for polymyxin resistance. Structure. 2005;13:929–942
  34. Gomez-Garces JL, Aracil B, Gil Y, Burillo A. Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs. J. Chemother. 2009;21:267–271
  35. Gunn JS, Miller SI. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J. Bacteriol. 1996;178:6857–6864
  36. Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, et al. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob. Agents Chemother. 2007;51:376–378
  37. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 2008;52:351–352
  38. Hejnar P, Kolar M, Hajek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ. Palacki Olomuc Fac. Med. 1999;142:73–77
  39. Hernan RC, Karina B, Gabriela G, Marcela N, Carlos V, Angela F. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 2009;65:188–191
  40. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, et al. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 2005;43:5085–5090
  41. Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 2004;54:1057–1061
  42. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 2009;30:666–671
  43. Igumbor E, Gwanzura L, Chirara M, Obi C, Muza D. Antibiotic sensitivity and plasmid profiles of Pseudomonas aeruginosa. Cent. Afr. J. Med. 2000;46:296–300
  44. Iroha EO, Kesah CN, Egri-Okwaji MT, Odugbemi TO. Bacterial eye infection in neonates, a prospective study in a neonatal unit. West Afr. J. Med. 1998;17:168–172
  45. Ito-Kagawa M, Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J. Antibiot. (Tokyo). 1980;33:1551–1555
  46. Jones RN, Stilwell MG, Rhomberg PR, Sader HS. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997–2007). Diagn. Microbiol. Infect. Dis. 2009;65:331–334
  47. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother. 2008;62:45–55
  48. Kato A, Latifi T, Groisman EA. Closing the loop: the PmrA/PmrB two-component system negatively controls expression of its posttranscriptional activator PmrD. Proc. Natl. Acad. Sci. U.S.A. 2003;100:4706–4711
  49. Keen EF, Robinson BJ, Hospenthal DR, Aldous WK, Wolf SE, Chung KK, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns. 2010;
  50. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 2008;62:895–904
  51. Kline T, Trent MS, Stead CM, Lee MS, Sousa MC, Felise HB, et al. Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg. Med. Chem. Lett. 2008;18:1507–1510
  52. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 2007;60:1163–1167
  53. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti Infect. Ther. 2007;5:811–821
  54. Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 2005;55:954–957
  55. Lapteva TA, Bazhenov LG, Suiumova AS, Shabanova NG. Identification and sensitivity to antimicrobial drugs of enterobacteria isolated from patients with suppurative, inflammatory diseases. Antibiot. Khimioter. 1993;38:35–40
  56. Lee YT, Huang LY, Chiang DH, Chen CP, Chen TL, Wang FD, et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int. J. Antimicrob. Agents. 2009;34:580–584
  57. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2006;50:2946–2950
  58. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 2007;45:594–598
  59. MacKenzie FM, Smith SV, Milne KE, Griffiths K, Legge J, Gould IM. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. J. Cyst. Fibros. 2004;3:151–157
  60. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 2000;31:101–106
  61. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit. Care Med. 2008;36:807–811
  62. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 2003;50:205–217
  63. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter s in Asia-Pacific nations: report from the SENTRY Surveillance Program. J. Antimicrob. Chemother. 2009;63:55–59
  64. Mezzatesta ML, Trovato G, Gona F, Nicolosi VM, Nicolosi D, Carattoli A, et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob. 2008;7:4
  65. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 2010;16:184–186
  66. Miftode E, Dorneanu O, Leca D, Teodor A, Mihalache D, Filip O, et al. Antimicrobial resistance profile of E. coli and Klebsiella s from urine in the Infectious Diseases Hospital Iasi. Rev. Med. Chir Soc. Med. Nat. Iasi. 2008;112:478–482
  67. Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J. Antimicrob. Chemother. 2010;65:82–90
  68. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1984;26:539–545
  69. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 2004;186:575–579
  70. Newton BA. The properties and mode of action of the polymyxins. Bacteriol. Rev. 1956;20:14–27
  71. Nicas TI, Hancock RE. Alteration of susceptibility to EDTA, polymyxin B and gentamicin in Pseudomonas aeruginosa by divalent cation regulation of outer membrane protein H1. J. Gen. Microbiol. 1983;129:509–517
  72. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 2008;68:223–240
  73. Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax. 2003;58:794–796
  74. Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. J. Med. Assoc. Thai. 2008;91(Suppl 3):S21–27
  75. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 2002;71:635–700
  76. Reeves PR, Hobbs M, Valvano MA, Skurnik M, Whitfield C, Coplin D, et al. Bacterial polysaccharide synthesis and gene nomenclature. Trends Microbiol. 1996;4:495–503
  77. Rose F, Heuer KU, Sibelius U, Hombach-Klonisch S, Kiss L, Seeger W, et al. Targeting lipopolysaccharides by the nontoxic polymyxin B nonapeptide sensitizes resistant Escherichia coli to the bactericidal effect of human neutrophils. J. Infect. Dis. 2000;182:191–199
  78. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents. 2009;34:506–515
  79. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. 2007;27:980–987
  80. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry. 1979;18:4425–4430
  81. Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother. 2002;49:403–406
  82. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 2006;50:3166–3169
  83. Sung H, Choi SJ, Yoo S, Kim MN. In vitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii. Korean J. Lab. Med. 2007;27:111–117
  84. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2010;54:1160–1164
  85. Tan TY, Hsu LY, Koh TH, Ng LS, Tee NW, Krishnan P, et al. Antibiotic resistance in gram-negative bacilli: a Singapore perspective. Ann. Acad. Med. Singapore. 2008;37:819–825
  86. Tan TY, Ng SY. The in-vitro activity of colistin in gram-negative bacteria. Singapore Med. J. 2006;47:621–624
  87. Tognim MC, Gales AC, Penteado AP, Silbert S, Sader HS. Dissemination of IMP-1 metallo- beta -lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect. Control Hosp. Epidemiol. 2006;27:742–747
  88. Tsubery H, Ofek I, Cohen S, Fridkin M. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria. J. Med. Chem. 2000;43:3085–3092
  89. Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients. Indian J. Pathol. Microbiol. 2008;51:200–203
  90. Walkty A, Decorby M, Nichol K, Mulvey MR, Hoban D, Zhanel G. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn. Microbiol. Infect. Dis. 2008;61:217–221
  91. Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 1985;28:107–112
  92. Winfield MD, Groisman EA. Phenotypic differences between Salmonella and Escherichia coli resulting from the disparate regulation of homologous genes. Proc. Natl. Acad. Sci. U.S.A. 2004;101:17162–17167
  93. Winfield MD, Latifi T, Groisman EA. Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis. J. Biol. Chem. 2005;280:14765–14772
  94. Yan A, Guan Z, Raetz CR. An undecaprenyl phosphate-aminoarabinose flippase required for polymyxin resistance in Escherichia coli. J. Biol. Chem. 2007;282:36077–36089
  95. Yang QW, Xu YC, Chen MJ, Hu YJ, Ni YX, Sun JY, et al. Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005. Zhonghua Yi Xue Za Zhi. 2007;87:2753–2758
  96. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 2009;58:138–144
  97. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Rev. Anti Infect. Ther. 2006;4:9–25

PII: S1368-7646(10)00031-2

doi: 10.1016/j.drup.2010.05.002

Drug Resistance Updates
Volume 13, Issue 4 , Pages 132-138 , August 2010

Article Tools

* Image Usage & Resolution